Back to results

Titanium Fusion Implant in Combination With Trans-iliac Screws for Insufficiency Fractures of the Pelvis (TIKTIS)

Primary Purpose

Pelvic Fracture, Insufficiency Fractures, Mobility Limitation

Status

Recruiting

Phase

Not Applicable

Locations

Germany

Study Type

Interventional

Intervention

iFuse-3D implant

About this trial

This is an interventional treatment trial for Pelvic Fracture focused on measuring Fracture Fixation, Fragility Fractures, Pelvis, Surgical Procedures, Minimal Invasive

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Legal capacity, capacity to inform
Presence of a written declaration of consent by the patient
Age: ≥ 60 years
Acute or subacute (less than 2 months) posterior pelvic girdle pain associated with low energy trauma or occurring spontaneously
Diagnosis confirmed by CT and/or MRI
The fracture corresponds to types OF3 and OF4 of the OF Pelvis classification.
Prior to the fracture, there was free, non-wheelchair mobility (Functional Mobility Score of 2 or higher)

Exclusion Criteria:

Diagnosed uncontrolled psychiatric illness (e.g. dementia, schizophrenia, major depression, personality disorder) that could affect study participation or reporting of findings
History of pelvic fracture within one year with evidence of failure of fracture to heal or internal fixation of the pelvic ring of any type
Patients unable to ambulate before the fracture
Patient has had lumbar instrumentation of more than two vertebrae and/or instrumentation of S1 in the past
Additional fractures that limit mobility
OF-P associated with benign or malignant tumours of the pelvis
Abnormal neurological condition that could affect study participation
An unusual clinical condition associated with a high risk of not being able to follow up (e.g. COPD, severe heart failure, Parkinson's disease, autoimmune diseases)
Any pelvic condition or anatomical feature that makes surgery impracticable
Known allergy to titanium or titanium alloys
Known opioid abuse for chronic pain syndromes
Participation in other interventional trials
Lack of surgical capability
Persons in a dependent/employee relationship with the sponsor or investigator
Placement in an institution due to court or administrative order.

Sites / Locations

Diakonie KrankenhausRecruiting
University Medical Center of the Johannes Gutenberg University Mainz
Helios Universitätsklinikum WuppertalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

iFuse-3D

Arm Description

Titanium fusion implant in combination with trans-iliac screws

Outcomes

Primary Outcome Measures

Proportion of patients who regain their pre-fracture mobility as measured by the FMS by the time of hospital discharge

The proportion is shown with frequencies and corresponding percentages.

Secondary Outcome Measures

Proportion of patients who achieve pre-fracture mobility within six weeks.

The proportion is shown with frequencies and corresponding percentages.

Proportion of patients who achieve pre-fracture mobility at three months.

The proportion is shown with frequencies and corresponding percentages.

Proportion of patients who achieve pre-fracture mobility at six months.

The proportion is shown with frequencies and corresponding percentages.

Proportion of patients who achieve pre-fracture mobility at 12 months.

The proportion is shown with frequencies and corresponding percentages.

Proportion of patients who achieved an FMS ≥ 2 (= walking with assistive devices) at discharge.

The proportion is shown with frequencies and corresponding percentages.

Proportion of patients who achieved an FMS ≥ 2 within six weeks.

The proportion is shown with frequencies and corresponding percentages.

Proportion of patients who achieved an FMS ≥ 2 at three months.

The proportion is shown with frequencies and corresponding percentages.

Proportion of patients who achieved an FMS ≥ 2 at six months.

The proportion is shown with frequencies and corresponding percentages.

Proportion of patients who achieved an FMS ≥ 2 at 12 months.

The proportion is shown with frequencies and corresponding percentages.

Change in posterior pelvic girdle pain at rest and when attempting to walk measured by a NRS (0-10) within six weeks.

Appropriate measures of location such as medians/quartiles are calculated. Appropriate significance tests will be applied.

Change in posterior pelvic girdle pain at rest and when attempting to walk measured by a NRS (0-10) at three months.

Appropriate measures of location such as medians/quartiles are calculated. Appropriate significance tests will be applied.

Change in posterior pelvic girdle pain at rest and when attempting to walk measured by a NRS (0-10) at six months.

Appropriate measures of location such as medians/quartiles are calculated. Appropriate significance tests will be applied.

Change in posterior pelvic girdle pain at rest and when attempting to walk measured by a NRS (0-10) at 12 months.

Appropriate measures of location such as medians/quartiles are calculated. Appropriate significance tests will be applied.

Timed up and go test after six weeks.

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Timed up and go test after three months.

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Timed up and go test after six months.

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Timed up and go test after 12 months.

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Opioid consumption and osteoporosis medication in the last six weeks.

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Opioid consumption and osteoporosis medication in the last three months.

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Opioid consumption and osteoporosis medication in the last six months.

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Opioid consumption and osteoporosis medication in the last 12 months.

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Change in quality of life measured by the EuroQol-5D-3L after six weeks.

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Change in quality of life measured by the EuroQol-5D-3L after three months.

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Change in quality of life measured by the EuroQol-5D-3L after six months.

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Change in quality of life measured by the EuroQol-5D-3L after 12 months.

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Proportion of screws or iFuse fractures.

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. If necessary, appropriate significance tests are applied.

Proportion of screw sintering.

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. If necessary, appropriate significance tests are applied.

Proportion of sintering/migration of the iFuse implant.

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. If necessary, appropriate significance tests are applied.

Proportion of radiological signs of loosening.

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. If necessary, appropriate significance tests are applied.

Proportion of infections.

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. If necessary, appropriate significance tests are applied.

Full Information

NCT ID

NCT05367505

First Posted

May 4, 2022

Last Updated

April 3, 2023

Sponsor

University of Witten/Herdecke

Collaborators

SI-BONE, Inc., Johannes Gutenberg University Mainz

1. Study Identification

Unique Protocol Identification Number

NCT05367505

Brief Title

Titanium Fusion Implant in Combination With Trans-iliac Screws for Insufficiency Fractures of the Pelvis

Acronym

TIKTIS

Official Title

Prospective Pilot Study With a Titanium Fusion Implant in Combination With Trans-iliac Screws for Insufficiency Fractures of the Pelvis

Study Type

Interventional

2. Study Status

Record Verification Date

April 2023

Overall Recruitment Status

Recruiting

Study Start Date

January 9, 2023 (Actual)

Primary Completion Date

December 1, 2023 (Anticipated)

Study Completion Date

December 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

University of Witten/Herdecke

Collaborators

SI-BONE, Inc., Johannes Gutenberg University Mainz

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

Many approaches to the surgical treatment of OF-P have been tried, but no one method has stood out as particularly successful. The placement of three implants, including implants that could minimise motion in the sacroiliac joint through early fixation and long-term fusion of the sacroiliac joint, can prevent micromotion in the fracture and thereby improve the clinical outcome of OF-Ps. The iFuse-3D implant was shown to be safe and effective for chronic sacroiliac pain in non-osteoporotic patients. The primary aim is to assess the proportion of patients operated on using iFuse-3D in conjunction with transiliac-transsacral screws who regain pre-fracture mobility by the time of hospital discharge.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Pelvic Fracture, Insufficiency Fractures, Mobility Limitation

Keywords

Fracture Fixation, Fragility Fractures, Pelvis, Surgical Procedures, Minimal Invasive

7. Study Design

Primary Purpose

Treatment

Study Phase

Not Applicable

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title

iFuse-3D

Arm Type

Experimental

Arm Description

Titanium fusion implant in combination with trans-iliac screws

Intervention Type

Device

Intervention Name(s)

iFuse-3D implant

Intervention Description

The iFuse Implant System consists of cannulated triangular titanium implants (Ti 6AI4V ELI, ASTM F136) with a porous coating of commercially pure titanium plasma spray (C.P. Ti, ASTM F1580) and a setting instrument. The coating and special shape of the implants prevent rotation or displacement of the sacroiliac (SI) joint. The placement instrument uses guide pins to achieve precise placement.

Primary Outcome Measure Information:

Title

Proportion of patients who regain their pre-fracture mobility as measured by the FMS by the time of hospital discharge

Description

The proportion is shown with frequencies and corresponding percentages.

Time Frame

Time 8 days (discharge) after surgery

Secondary Outcome Measure Information:

Title

Proportion of patients who achieve pre-fracture mobility within six weeks.

Description

The proportion is shown with frequencies and corresponding percentages.

Time Frame

Time six weeks after surgery

Title

Proportion of patients who achieve pre-fracture mobility at three months.

Description

The proportion is shown with frequencies and corresponding percentages.

Time Frame

Time three months after surgery

Title

Proportion of patients who achieve pre-fracture mobility at six months.

Description

The proportion is shown with frequencies and corresponding percentages.

Time Frame

Time six months after surgery

Title

Proportion of patients who achieve pre-fracture mobility at 12 months.

Description

The proportion is shown with frequencies and corresponding percentages.

Time Frame

Time 12 months after surgery

Title

Proportion of patients who achieved an FMS ≥ 2 (= walking with assistive devices) at discharge.

Description

The proportion is shown with frequencies and corresponding percentages.

Time Frame

Time 8 days (discharge) after surgery

Title

Proportion of patients who achieved an FMS ≥ 2 within six weeks.

Description

The proportion is shown with frequencies and corresponding percentages.

Time Frame

Time six weeks after surgery

Title

Proportion of patients who achieved an FMS ≥ 2 at three months.

Description

The proportion is shown with frequencies and corresponding percentages.

Time Frame

Time three months after surgery

Title

Proportion of patients who achieved an FMS ≥ 2 at six months.

Description

The proportion is shown with frequencies and corresponding percentages.

Time Frame

Time six months after surgery

Title

Proportion of patients who achieved an FMS ≥ 2 at 12 months.

Description

The proportion is shown with frequencies and corresponding percentages.

Time Frame

Time 12 months after surgery

Title

Change in posterior pelvic girdle pain at rest and when attempting to walk measured by a NRS (0-10) within six weeks.

Description

Appropriate measures of location such as medians/quartiles are calculated. Appropriate significance tests will be applied.

Time Frame

Time six weeks after surgery

Title

Change in posterior pelvic girdle pain at rest and when attempting to walk measured by a NRS (0-10) at three months.

Description

Appropriate measures of location such as medians/quartiles are calculated. Appropriate significance tests will be applied.

Time Frame

Time three months after surgery

Title

Change in posterior pelvic girdle pain at rest and when attempting to walk measured by a NRS (0-10) at six months.

Description

Appropriate measures of location such as medians/quartiles are calculated. Appropriate significance tests will be applied.

Time Frame

Time six months after surgery

Title

Change in posterior pelvic girdle pain at rest and when attempting to walk measured by a NRS (0-10) at 12 months.

Description

Appropriate measures of location such as medians/quartiles are calculated. Appropriate significance tests will be applied.

Time Frame

Time 12 months after surgery

Title

Timed up and go test after six weeks.

Description

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Time Frame

Time six weeks after surgery

Title

Timed up and go test after three months.

Description

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Time Frame

Time three months after surgery

Title

Timed up and go test after six months.

Description

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Time Frame

Time six months after surgery

Title

Timed up and go test after 12 months.

Description

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Time Frame

Time 12 months after surgery

Title

Opioid consumption and osteoporosis medication in the last six weeks.

Description

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Time Frame

Time six weeks after surgery

Title

Opioid consumption and osteoporosis medication in the last three months.

Description

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Time Frame

Time three months after surgery

Title

Opioid consumption and osteoporosis medication in the last six months.

Description

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Time Frame

Time six months after surgery

Title

Opioid consumption and osteoporosis medication in the last 12 months.

Description

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Time Frame

Time 12 months after surgery

Title

Change in quality of life measured by the EuroQol-5D-3L after six weeks.

Description

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Time Frame

Time six weeks after surgery

Title

Change in quality of life measured by the EuroQol-5D-3L after three months.

Description

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Time Frame

Time three months after surgery

Title

Change in quality of life measured by the EuroQol-5D-3L after six months.

Description

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Time Frame

Time six months after surgery

Title

Change in quality of life measured by the EuroQol-5D-3L after 12 months.

Description

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. Appropriate significance tests will be applied.

Time Frame

Time 12 months after surgery

Title

Proportion of screws or iFuse fractures.

Description

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. If necessary, appropriate significance tests are applied.

Time Frame

Time within 12 months

Title

Proportion of screw sintering.

Description

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. If necessary, appropriate significance tests are applied.

Time Frame

Time within 12 months

Title

Proportion of sintering/migration of the iFuse implant.

Description

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. If necessary, appropriate significance tests are applied.

Time Frame

Time within 12 months

Title

Proportion of radiological signs of loosening.

Description

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. If necessary, appropriate significance tests are applied.

Time Frame

Time within 12 months

Title

Proportion of infections.

Description

Appropriate measures of location such as frequencies/percentages or medians/quartiles are calculated. If necessary, appropriate significance tests are applied.

Time Frame

Time within 12 months

10. Eligibility

Sex

All

Minimum Age & Unit of Time

60 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Legal capacity, capacity to inform Presence of a written declaration of consent by the patient Age: ≥ 60 years Acute or subacute (less than 2 months) posterior pelvic girdle pain associated with low energy trauma or occurring spontaneously Diagnosis confirmed by CT and/or MRI The fracture corresponds to types OF3 and OF4 of the OF Pelvis classification. Prior to the fracture, there was free, non-wheelchair mobility (Functional Mobility Score of 2 or higher) Exclusion Criteria: Diagnosed uncontrolled psychiatric illness (e.g. dementia, schizophrenia, major depression, personality disorder) that could affect study participation or reporting of findings History of pelvic fracture within one year with evidence of failure of fracture to heal or internal fixation of the pelvic ring of any type Patients unable to ambulate before the fracture Patient has had lumbar instrumentation of more than two vertebrae and/or instrumentation of S1 in the past Additional fractures that limit mobility OF-P associated with benign or malignant tumours of the pelvis Abnormal neurological condition that could affect study participation An unusual clinical condition associated with a high risk of not being able to follow up (e.g. COPD, severe heart failure, Parkinson's disease, autoimmune diseases) Any pelvic condition or anatomical feature that makes surgery impracticable Known allergy to titanium or titanium alloys Known opioid abuse for chronic pain syndromes Participation in other interventional trials Lack of surgical capability Persons in a dependent/employee relationship with the sponsor or investigator Placement in an institution due to court or administrative order.

Central Contact Person:

First Name & Middle Initial & Last Name or Official Title & Degree

Katharina Graf

Phone

+49 202 896

Ext

5614

katharina.graf@uni-wh.de

First Name & Middle Initial & Last Name or Official Title & Degree

René Geißen, Dr.

Phone

+49 202 896

Ext

5613

rene.geissen@uni-wh.de

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Erol Gercek, Prof.

Organizational Affiliation

University Medical Center of the Johannes Gutenberg University Mainz

Official's Role

Principal Investigator

Facility Information:

Facility Name

Diakonie Krankenhaus

City

Bad Kreuznach

ZIP/Postal Code

55543

Country

Germany

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Frank Hartmann, Prof. Dr.

hartmafr@kreuznacherdiakonie.de

Facility Name

University Medical Center of the Johannes Gutenberg University Mainz

City

Mainz

ZIP/Postal Code

55131

Country

Germany

Individual Site Status

Not yet recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Erol Gercek, Prof.

erol.gercek@unimedizin-mainz.de

Facility Name

Helios Universitätsklinikum Wuppertal

City

Wuppertal

ZIP/Postal Code

42283

Country

Germany

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Koroush Kabir, Dr.

Phone

+49 202 896-3301

koroush.kabir@helios-gesundheit.de

First Name & Middle Initial & Last Name & Degree

Koroush Kabir, Dr.

12. IPD Sharing Statement

Citations:

PubMed Identifier

24762143

Citation

Sullivan MP, Baldwin KD, Donegan DJ, Mehta S, Ahn J. Geriatric fractures about the hip: divergent patterns in the proximal femur, acetabulum, and pelvis. Orthopedics. 2014 Mar;37(3):151-7. doi: 10.3928/01477447-20140225-50.

Results Reference

background

PubMed Identifier

29684740

Citation

Kannus P, Niemi S, Parkkari J, Sievanen H. Continuously declining incidence of hip fracture in Finland: Analysis of nationwide database in 1970-2016. Arch Gerontol Geriatr. 2018 Jul-Aug;77:64-67. doi: 10.1016/j.archger.2018.04.008. Epub 2018 Apr 17.

Results Reference

background

PubMed Identifier

26319676

Citation

Kannus P, Parkkari J, Niemi S, Sievanen H. Low-Trauma Pelvic Fractures in Elderly Finns in 1970-2013. Calcif Tissue Int. 2015 Dec;97(6):577-80. doi: 10.1007/s00223-015-0056-8. Epub 2015 Aug 29.

Results Reference

background

PubMed Identifier

24419459

Citation

Nanninga GL, de Leur K, Panneman MJ, van der Elst M, Hartholt KA. Increasing rates of pelvic fractures among older adults: The Netherlands, 1986-2011. Age Ageing. 2014 Sep;43(5):648-53. doi: 10.1093/ageing/aft212. Epub 2014 Jan 12.

Results Reference

background

PubMed Identifier

26418971

Citation

Andrich S, Haastert B, Neuhaus E, Neidert K, Arend W, Ohmann C, Grebe J, Vogt A, Jungbluth P, Rosler G, Windolf J, Icks A. Epidemiology of Pelvic Fractures in Germany: Considerably High Incidence Rates among Older People. PLoS One. 2015 Sep 29;10(9):e0139078. doi: 10.1371/journal.pone.0139078. eCollection 2015.

Results Reference

background

PubMed Identifier

27448040

Citation

Maier GS, Kolbow K, Lazovic D, Horas K, Roth KE, Seeger JB, Maus U. Risk factors for pelvic insufficiency fractures and outcome after conservative therapy. Arch Gerontol Geriatr. 2016 Nov-Dec;67:80-5. doi: 10.1016/j.archger.2016.06.020. Epub 2016 Jul 15.

Results Reference

background

PubMed Identifier

28359073

Citation

Rommens PM, Wagner D, Hofmann A. Fragility Fractures of the Pelvis. JBJS Rev. 2017 Mar 21;5(3):e3. doi: 10.2106/JBJS.RVW.16.00057. No abstract available.

Results Reference

background

PubMed Identifier

27077891

Citation

Breuil V, Roux CH, Carle GF. Pelvic fractures: epidemiology, consequences, and medical management. Curr Opin Rheumatol. 2016 Jul;28(4):442-7. doi: 10.1097/BOR.0000000000000293.

Results Reference

background

PubMed Identifier

21513936

Citation

Pohlemann T, Stengel D, Tosounidis G, Reilmann H, Stuby F, Stockle U, Seekamp A, Schmal H, Thannheimer A, Holmenschlager F, Gansslen A, Rommens PM, Fuchs T, Baumgartel F, Marintschev I, Krischak G, Wunder S, Tscherne H, Culemann U. Survival trends and predictors of mortality in severe pelvic trauma: estimates from the German Pelvic Trauma Registry Initiative. Injury. 2011 Oct;42(10):997-1002. doi: 10.1016/j.injury.2011.03.053. Epub 2011 Apr 22.

Results Reference

background

PubMed Identifier

28272751

Citation

Andrich S, Haastert B, Neuhaus E, Neidert K, Arend W, Ohmann C, Grebe J, Vogt A, Jungbluth P, Thelen S, Windolf J, Icks A. Excess Mortality After Pelvic Fractures Among Older People. J Bone Miner Res. 2017 Sep;32(9):1789-1801. doi: 10.1002/jbmr.3116. Epub 2017 May 8.

Results Reference

background

PubMed Identifier

34844577

Citation

Ullrich BW, Schnake KJ, Spiegl UJA, Schenk P, Mendel T, Behr L, Bula P, Flucht LB, Franck A, Gercek E, Gruninger S, Hartung P, Jacobs C, Katscher S, Klauke F, Liepold K, Muller CW, Muller M, Osterhoff G, Partenheimer A, Piltz S, Riehle M, Sauer D, Scheyerer MJ, Schleicher P, Schmeiser G, Schmidt R, Scholz M, Siekmann H, Sprengel K, Stoevesandt D, Verheyden A, Zimmermann V; Spine Section of the German Society for Orthopaedics and Trauma. OF-Pelvis classification of osteoporotic sacral and pelvic ring fractures. BMC Musculoskelet Disord. 2021 Nov 29;22(1):992. doi: 10.1186/s12891-021-04882-6.

Results Reference

background

PubMed Identifier

23178479

Citation

Hammer N, Lingslebe U, Aust G, Milani TL, Hadrich C, Steinke H. Ultimate stress and age-dependent deformation characteristics of the iliotibial tract. J Mech Behav Biomed Mater. 2012 Dec;16:81-6. doi: 10.1016/j.jmbbm.2012.04.025. Epub 2012 Oct 30.

Results Reference

background

Learn more about this trial

Titanium Fusion Implant in Combination With Trans-iliac Screws for Insufficiency Fractures of the Pelvis

We'll reach out to this number within 24 hrs